Extended-Release Buprenorphine on Mobile Pharmacy Clinic for Opioid Use Disorder

This study aims to explore the use of an extended-release form of buprenorphine, known as BRIXADI, delivered through a mobile pharmacy clinic. It focuses on individuals who may benefit from a sustained-release medication for certain medical needs. The goal is to see if this method of delivery is both acceptable and feasible over a six-month period. This is significant as it could offer a more flexible and accessible way to receive important medication, particularly for those who have difficulty accessing traditional healthcare facilities. Participants in the study will have the option to choose, along with their clinician, whether they want to receive the medication in weekly or monthly doses. The medication is administered as an injection under the skin, and it will be provided at no cost for the duration of the study. Researchers will gather data from medical visits and records over the six months to evaluate how well this approach works. This may help in understanding the benefits and any challenges involved in using a mobile pharmacy clinic to distribute extended-release medications.